The future of IPF: current mysteries and challenges

Symposium
Chairs: V. Poletti (Forli, Italy), U. Costabel (Essen, Germany)
Aims: The aim is to improve our understanding of the molecular mechanisms and clinical phenotypes of IPF as well as the therapeutic perspectives.

Heterogeneity of the natural history and predictors of mortality T. King (San Francisco, United States of America)
How are we going to treat IPF patients in the future? A. Wells (London, United Kingdom)